The goal of this project is to identify molecular characteristics of multi-drug resistance in high-risk neuroblastoma patients with single-cell technology. We propose a paradigm-shift approach to map mutations into a single cell and identify sub-clones by molecular similarity of individual cells. Neuroblastoma is the common solid tumor in children, and it accounts for 15% of deaths from cancer in children. Here, we propose to identify multidrug-resistant mutations with Next Generation Sequencing (NGS) based on mutation frequency changes (from minority to majority) due to treatment selection. These NGS-identified mutations will be localized into individual cells with targeted single-cell RNA-seq to show that these mutations exist in a clone (a group of single-cells) and the clones expand during treatment. Finally, the resistant sub-clones will be isolated or generated for functional assays and distributed to research community. This approach shifts the paradigm of tumor molecular characterization by clustering molecularly similar cells into a clone rather than isolating a clone (often with experimental bias) for characterization. The results have direct and immediate impacts on current treatment of neuroblastoma. The molecular profiles of resistant clones can be developed into sensitive PCR assays for early detection of drug-resistance at diagnosis, and for personalized therapies to overcome treatment resistance at specific patients (who have specific sub-clones during chemotherapy). The single-cell approach that we develop in this proposal would be directly relevant to studies of other childhood and adult cancers as well.

Public Health Relevance

The goal of this project is to identify molecular characteristics of multi-drug resistance in high-risk neuroblastoma patients with single-cell technology. We propose a paradigm-shift approach to map mutations into a single cell and identify sub-clones by molecular similarity of individual cells. The results have direct and immediate impacts on current treatment of neuroblastoma. The molecular profiles of resistant clones can be developed into sensitive PCR assays for early detection of drug-resistance at diagnosis, and for personalized therapies to overcome treatment resistance at specific patients (who have specific sub-clones during chemotherapy).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA197903-05
Application #
9960439
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Ossandon, Miguel
Project Start
2016-07-01
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Southern California
Department
Pathology
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Jiao, Xuanmao; Velasco-Velázquez, Marco A; Wang, Min et al. (2018) CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. Cancer Res 78:1657-1671
Chen, Xuelian; Wen, Qin; Stucky, Andres et al. (2018) Relapse pathway of glioblastoma revealed by single-cell molecular analysis. Carcinogenesis 39:931-936
Zeng, Yunjing; Gao, Li; Luo, Xiaoqing et al. (2018) Microfluidic enrichment of plasma cells improves treatment of multiple myeloma. Mol Oncol 12:1004-1011
Chen, Yan; Millstein, Joshua; Liu, Yao et al. (2018) Single-Cell Digital Lysates Generated by Phase-Switch Microfluidic Device Reveal Transcriptome Perturbation of Cell Cycle. ACS Nano 12:4687-4694
Stucky, Andres; Chen, Xuelian; Zhong, Jiang F (2018) Gene Manipulation with Micro RNAs at Single-Human Cancer Cell. Methods Mol Biol 1733:215-223
Li, Shengwen Calvin; Vu, Long T; Luo, Jane Jianying et al. (2017) Tissue Elasticity Bridges Cancer Stem Cells to the Tumor Microenvironment Through microRNAs: Implications for a ""Watch-and-Wait"" Approach to Cancer. Curr Stem Cell Res Ther 12:455-470
Liu, Jun; Zhong, Jiang F; Zhang, Xi et al. (2017) Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol 10:35
Zhang, Cheng; Yang, Shi-Jie; Wen, Qin et al. (2017) Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. J Cancer 8:85-96